Researchers around the world have tried many ways, and for many years, to generate neurons in the lab so they could study them better. Neurons-on-demand might also provide a therapeutic option for replacing neurons lost in neurodegenerative conditions, such as Parkinson's disease.
(0)
TORONTO and CAMBRIDGE, Mass., May 12, 2021 (GLOBE NEWSWIRE) ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced the appointment of Rudolph Tanzi, Ph.D, as Chair of the Company s scientific advisory board (SAB). Dr. Tanzi is the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard University and Vice-Chair of Neurology, Director of the Genetics and Aging Research Unit, and Co-Director of the Henry and Allison McCance Center for Brain Health at Massachusetts General Hospital.
The Vatican s Pontifical Council for Culture and The Cura Foundation Unite to Prevent
Global Leaders in Science, Faith, Medicine and Technology Gather for the Fifth International Vatican Conference
News provided by
Share this article
Share this article
VATICAN CITY and NEW YORK, April 15, 2021 /PRNewswire/ The Vatican s Pontifical Council for Culture and The Cura Foundation s Fifth International Vatican Conference will be held on May 6-8, 2021. The conference will unite the foremost leading physicians, scientists, leaders of faith, ethicists, patient advocates, policymakers, philanthropists and influencers to engage in powerful conversations on the latest breakthroughs in medicine, health care delivery and prevention, as well as the anthropological scientific and cultural impact of technological advances.
Novel Drug Prevents Amyloid Plaques, a Hallmark of Alzheimer’s Disease In animal models, the new compound modulated a key enzyme, reducing or eliminating production of problematic protein fragments; human clinical trials needed March 02, 2021 | Scott LaFee
News release
Amyloid plaques are pathological hallmarks of Alzheimer’s disease (AD) clumps of misfolded proteins that accumulate in the brain, disrupting and killing neurons and resulting in the progressive cognitive impairment that is characteristic of the widespread neurological disorder.
In a new study, published March 2, 2021 in the
Journal of Experimental Medicine (JEM), researchers at University of California San Diego School of Medicine, Massachusetts General Hospital and elsewhere have identified a new drug that could prevent AD by modulating, rather than inhibiting, a key enzyme involved in forming amyloid plaques.
Novel Drug Prevents Amyloid Plaques, a Hallmark of Alzheimer s Disease scienceblog.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from scienceblog.com Daily Mail and Mail on Sunday newspapers.